Spruce Biosciences (NASDAQ:SPRB) focuses on developing novel therapies for rare endocrine disorders. The company is dedicated to advancing treatments that can significantly improve the lives of patients suffering from these conditions. Their primary project centers around tildacerfont, a promising drug candidate aimed at addressing congenital adrenal hyperplasia, a rare disorder impacting the adrenal glands. Spruce Biosciences is committed to pushing the boundaries of medical research to provide new hope for patients with limited treatment options, ultimately aiming to become a beacon of innovation in the rare disease therapeutic space.